RenovoRx/$RNXT
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About RenovoRx
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Ticker
$RNXT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
10
ISIN
US75989R1077
Website
RenovoRx Metrics
BasicAdvanced
$48M
-
-$0.39
1.32
-
Price and volume
Market cap
$48M
Beta
1.32
52-week high
$1.45
52-week low
$0.75
Average daily volume
191K
Financial strength
Current ratio
9.07
Quick ratio
8.539
Long term debt to equity
1.414
Total debt to equity
2.151
Profitability
Gross margin (TTM)
60.83%
Net profit margin (TTM)
-4,232.50%
Operating margin (TTM)
-4,835.00%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-69.73%
Return on equity (TTM)
-136.13%
Valuation
Price to revenue (TTM)
142.92
Price to book
3.61
Price to tangible book (TTM)
3.61
Price to free cash flow (TTM)
-3.325
Free cash flow yield (TTM)
-30.08%
Free cash flow per share (TTM)
-39.10%
Growth
Earnings per share change (TTM)
-43.78%
3-year earnings per share growth (CAGR)
-31.24%
RenovoRx News
AllArticlesVideos
RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights
Business Wire·2 months ago
RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st
Business Wire·2 months ago
Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for RenovoRx stock?
RenovoRx (RNXT) has a market cap of $48M as of July 04, 2025.
What is the P/E ratio for RenovoRx stock?
The price to earnings (P/E) ratio for RenovoRx (RNXT) stock is 0 as of July 04, 2025.
Does RenovoRx stock pay dividends?
No, RenovoRx (RNXT) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next RenovoRx dividend payment date?
RenovoRx (RNXT) stock does not pay dividends to its shareholders.
What is the beta indicator for RenovoRx?
RenovoRx (RNXT) has a beta rating of 1.32. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.